Eurostar grant supports application of BioLizard’s AI expertise to Broken String’s INDUCE-seq® platform; Resulting technology, called SafeGuide, will enable faster, more cost-effective development of gene edited therapies like CRISPR.
Investment supports platform innovation, commercial scaling, and new service development; Infinity acquires the assets of Serimmune, Inc.
Illumina Ventures leads round to accelerate Arima’s clinical expansion.
Series C round led by Deep Track Capital with participation from additional new and existing investors; financing will fund early-to-mid-stage clinical studies for ATTO-1310 in chronic pruritus and ATTO-3712 in atopic dermatitis, and multiple earlier-stage multi-specific programs.
Your screen does not meet the requirements for generating previews. Adjust your screen width to exactly 1920px before proceeding, otherwise you'll not be able to generate previews.
